

AWARD NUMBER: CDMRPL-16-0-DM167102

TITLE: Evaluation of Hypotensive Resuscitation +/- Aeromedical Evacuation and the Effects of Oxygen Therapeutics During Prolonged Field Care in a Swine Polytrauma Model

PRINCIPAL INVESTIGATOR: LCDR Carolyn Gosztyla, MD

CONTRACTING ORGANIZATION: Naval Medical Research Center
503 Robert Grant Avenue
Silver Spring, MD 20910

REPORT DATE: AUG 2021

TYPE OF REPORT: ANNUAL

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE Aug 2021			2. REPORT TYPE Annual			3. DATES COVERED 01AUG2020-31JUL2021		
4. TITLE AND SUBTITLE Evaluation of Hypotensive Resuscitation +/- Aeromedical Evacuation and the Effects of Oxygen Therapeutics During Prolonged Field Care in a Swine Polytrauma Model						5a. CONTRACT NUMBER CDMRPL-16-0-DM167102		
						5b. GRANT NUMBER CDMRPL-16-0-DM167102		
						5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) LCDR Carolyn Gosztyla, MD Dr. Francoise Arnaud E-Mail: carolyn.e.gosztyla.mil@mail.mil francoise.arnaud.ctr@mail.mil						5d. PROJECT NUMBER DM167102		
						5e. TASK NUMBER		
						5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Naval Medical Research Center Uniformed Services University of the 503 Robert Grant Ave. Silver Spring MD Health Sciences 20910 4301 Jones Bridge Rd, Bethesda MD 20814						8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012						10. SPONSOR/MONITOR'S ACRONYM(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
13. SUPPLEMENTARY NOTES								
14. ABSTRACT In light of the potential for future conflicts in parts of the world where immediate evacuation of combat casualties might not be possible, research is needed to address knowledge gaps during prolonged field care and its effects on subsequent long range patient transport to definitive care. For example, there is no data available about the impact of prolonged hypotensive resuscitation on vital organ function in TBI and polytrauma patients. Novel resuscitation fluids that might provide efficient oxygenation to vital tissue beds in the PFC environment need to be assessed for efficacy, as they may improve pre-hospital care and subsequent outcome of combat casualties. The knowledge gained will be used to optimize care provided to our wounded service members as they are moved through the en route system. The proposed research will provide needed data on the impact of prolonged hypotensive resuscitation for 72 hours on neurotrauma and polytrauma casualties and identify possible safety risks associated with aero-medical evacuation of patients. It also assesses whether or not hypotensive resuscitation is actually the best modality (compared with normotensive) in this PFC scenario. This study will directly address improvement of combat casualty safety, morbidity and mortality.								
15. SUBJECT TERMS Prolonged field care; hypotensive resuscitation; hemorrhagic shock; aeromedical evacuation; oxygen therapeutics								
16. SECURITY CLASSIFICATION OF:				17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC		
a. REPORT	b. ABSTRACT	c. THIS PAGE	19b. TELEPHONE NUMBER (include area code)					
Unclassified	Unclassified	Unclassified	Unclassified	15				

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	8
5. Changes/Problems	9
6. Products	11
7. Participants & Other Collaborating Organizations	13
8. Special Reporting Requirements	14
9. Appendices	15

1. INTRODUCTION: *Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.*

The objective of this study is to confirm our hypotheses related to the possible adverse effects of Prolonged Field Care (PFC) and aeromedical evacuation (AE) on polytrauma patients, and to evaluate if the use of an Oxygen Therapeutic (OT) during PFC can improve oxygenation and outcomes. We will test this hypothesis in a swine polytrauma model. Data from this study could potentially aid in the improvement of safety recommendations for prolonged field care, en route care, and aeromedical evacuation of combat casualties.

Specific aims:

This study aims at addressing the following research questions:

- 1) How does prolonged hypotensive resuscitation over 72 hours affect physiology and neurophysiology in polytrauma casualties?
- 2) What are the effects of transport/aeromedical evacuation after prolonged hypotensive resuscitation on physiology and neurophysiology in polytrauma casualties?
- 3) Does an OT improve systemic and cerebral oxygen delivery under conditions of prolonged hypotension in polytrauma patients?

2. KEYWORDS: *Provide a brief list of keywords (limit to 20 words).*

Prolonged field care; hypotensive resuscitation; hemorrhagic shock; aeromedical evacuation; oxygen therapeutics

3. ACCOMPLISHMENTS: *The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction.*

What were the major goals of the project?

List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.

The objective of this study is to confirm our hypotheses related to the possible adverse effects of Prolonged Field Care (PFC) and aeromedical evacuation (AE) on polytrauma patients, and to evaluate if the use of an Oxygen Therapeutic (OT) during PFC can improve oxygenation and patient outcomes. We will test this hypothesis in a swine polytrauma model. Data from this study could potentially aid in the improvement of safety recommendations for prolonged field care, en route care, and aeromedical evacuation for combat casualties.

This study aims to address the following research questions:

- 1) How does prolonged hypotensive resuscitation over 72 hours affect physiology and neurophysiology in polytrauma casualties?
- 2) What are the effects of transport/aeromedical evacuation after prolonged hypotensive resuscitation on physiology and neurophysiology in polytrauma casualties?

3) Does an OT improve systemic and cerebral oxygen delivery under conditions of prolonged hypotension in polytrauma patients?

	Timeline	Method	Status
1) Specific Aim 1: Determine effects of 72-h prolonged hypotensive resuscitation (PHR) on physiology/neurophysiology in swine polytrauma model.			
Major Task 1: Obtain regulatory approvals (IACUC/ACURO)	Months		
Subtask 1: write/submit/obtain approval - IACUC protocol	1-2	writing	completed
Subtask 2: Submit animal protocol to ACURO and obtain approval	2-3	writing	completed
<i>Milestone(s) Achieved: obtained IACUC and ACURO approvals</i>	3	writing	completed
Major Task 2: Perform pilot study – optimize PHR swine model			
Subtask 1: determine optimal PHR experimental conditions for 77-h swine study	4-8	Animal experiments	Completed
Subtask 2: prepare team for prolonged experiments	4-8	Animal experiments	Completed
Subtask 3: Phase 1 histopathology & immunohistopathology preparation/analysis	4-10	Statistics/writing	ongoing
<i>Milestone(s) Achieved: Swine model optimized.</i>	10		ongoing
Major Task 3: Perform Phase 1 experiments – determine safety/efficacy of PHR vs prolonged hypotensive resuscitation (PNR)			
Subtask 1: Submit IACUC Protocol (for new study design)	34-36	Writing	ongoing
Subtask 2: Phase 1 Start experiments/analyze results	36-40	Animal experiments/data analysis	
<i>Milestone(s) Achieved: completed Phase 1 experiments.</i>	40		
2) Specific Aim 2: Determine effects of aeromedical evacuation (AE) after PHR on physiology/and neurophysiology in swine			
Major Task 4: Perform Phase 2 experiments – determine safety/efficacy of AE following PHR/PNR.			

Subtask 1: perform Phase 2 in-life experiments	40-42	Animal experiments	
Subtask 2: Phase 2 histopathology & immunohistopathology preparation/analysis	40-44	Statistics/writing	
<i>Milestone(s) Achieved: completed Phase 2 experiments.</i>	44		
3) Specific Aim 3: Determine effects of adding an oxygen therapeutic (OT) to PHR regimen on physiology/and neurophysiology in swine			
Major Task 4: Perform Phase 3 experiments – determine safety/efficacy of including OT in PHR/PNR.			
Subtask 1: perform Phase 3 in-life experiments	42-46	Animal experiments	
Subtask 2: Phase 3 histopathology & immunohistopathology preparation/analysis	46-48	Statistics/writing	
<i>Milestone(s) Achieved: completed Phase 3 experiments.</i>	48		
Major Task 5: Final data analysis and writing Final Report and manuscripts for peer-review.			
Subtask 1: analyze data	46-48	Statistics	
Subtask 1: write/submit Final Report	46-48	writing	
Subtask 1: prepare/submit manuscripts	46-48	writing	
<i>Milestone(s) Achieved: completed data analysis, submitted Final Report, and prepared manuscripts</i>	48		

What was accomplished under these goals?

For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.

As major activities during this reporting period;

- A new IACUC protocol has been drafted following the discussion with representatives from NMRC and the funders. This protocol requires a new design of the experiments to accomplish the specific aims – while we have discussed changing the anesthesia plan with the funder, additional refinement is required for the details of the protocol and discussion is ongoing with IACUC. In addition, we have reengaged HbO₂, Hemoglobin Oxygen Therapeutics LLC, the provider of the hemoglobin based oxygen carrier and are working on an experimental plan using their product in the coming months.

What opportunities for training and professional development has the project provided?

If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. “Training” activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. “Professional development” activities result in increased knowledge or skill in one’s area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.

The research team for this project has utilized several training animals to refine the surgical technique and identify areas for improvement in the proposed experimental design. There has been a learning curve using the wireless implantable telemetric devices and ongoing discussion with the manufacturer of this cutting edge technology has provided professional development opportunity on both sides of the project.

How were the results disseminated to communities of interest?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.

Not Applicable.

What do you plan to do during the next reporting period to accomplish the goals?

If this is the final report, state “Nothing to Report.”

Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.

A new IACUC protocol addressing the effects of a prolonged resuscitative phase is in progress, this will be submitted for approval and animal experiments will follow.

4. IMPACT: *Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:*

What was the impact on the development of the principal discipline(s) of the project?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).

.A new IACUC protocol is in progress.

What was the impact on other disciplines?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.

No impact to report.

What was the impact on technology transfer?

If there is nothing significant to report during this reporting period, state “Nothing to Report.” Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

No technology transfer to report.

What was the impact on society beyond science and technology?

If there is nothing significant to report during this reporting period, state “Nothing to Report.” Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

Nothing to Report.

5. CHANGES/PROBLEMS: *The PD/PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, “Nothing to Report,” if applicable:*

There is a question of Hemopure, the HbO2’s product that we are addressing with the supplier and with our legal department as the company is no longer producing this therapeutic but maintains a back supply of product - we would like to get legal permission to use this product for our study.

Changes in approach and reasons for change

Describe any changes in approach during the reporting period and reasons for these changes. Remember that significant changes in objectives and scope require prior approval of the agency.

A new IACUC protocol addressing the effects of a prolonged resuscitative phase is in progress, this will be submitted for approval. Upon approval, the final modifications in experimental design will be confirmed with the funding agency prior to initiating animal experiments.

Actual or anticipated problems or delays and actions or plans to resolve them

Describe problems or delays encountered during the reporting period and actions or plans to resolve them.

Nothing to report.

Changes that had a significant impact on expenditures

Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.

Nothing to report.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.

Significant changes in use or care of human subjects

N/A

Significant changes in use or care of vertebrate animals

N/A

Significant changes in use of biohazards and/or select agents

N/A

6. **PRODUCTS:** *List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state “Nothing to Report.”*

- **Publications, conference papers, and presentations**

Report only the major publication(s) resulting from the work under this award.

Journal publications. *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume; year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

No publication to report.

Books or other non-periodical, one-time publications. *Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

No publication to report.

Other publications, conference papers and presentations. *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.*

Nothing to report.

- **Website(s) or other Internet site(s)**

List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.

Nothing to report.

- **Technologies or techniques**

Identify technologies or techniques that resulted from the research activities. Describe the technologies or techniques were shared.

Nothing to report.

- **Inventions, patent applications, and/or licenses**

Identify inventions, patent applications with date, and/or licenses that have resulted from the research. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.

- Nothing to report.

Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment and /or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:

- *data or databases;*
- *physical collections;*
- *audio or video products;*
- *software;*
- *models;*
- *educational aids or curricula;*
- *instruments or equipment;*
- *research material (e.g., Germplasm; cell lines, DNA probes, animal models);*
- *clinical interventions;*
- *new business creation; and*
- *other.*

Nothing to report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate “no change”.

Personnel	Role	Percent Effort
LCDR Carolyn Gosztyla	PI	6
Col Debra Malone	AI	6
Dr. Francoise Arnaud	Scientist	10
Dr. Yaron Dayani	Scientist	5
Noemy Carballo	Research Assistant	10
Natalie Coschigano	Research Assistant	10
Jordan Hubbell	Research Assistant	9
Michael Hammett	Research Assistant	10
Fang Zhou Yang	Research Assistant	5
Ye Chen	Scientist	6
William Porter	Chamber Operator	6

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

If there is nothing significant to report during this reporting period, state “Nothing to Report.” If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.

No change.

What other organizations were involved as partners?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or

domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.

Provide the following information for each partnership:

Organization Name:

Location of Organization: (if foreign location list country)

Partner’s contribution to the project (identify one or more)

- *Financial support;*
- *In-kind support (e.g., partner makes software, computers, equipment, etc., available to project staff);*
- *Facilities (e.g., project staff use the partner’s facilities for project activities);*
- *Collaboration (e.g., partner’s staff work with project staff on the project);*
- *Personnel exchanges (e.g., project staff and/or partner’s staff use each other’s facilities, work at each other’s site); and*
- *Other.*

Nothing to report.

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: *For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ers.amedd.army.mil> for each unique award.*

QUAD CHARTS: *If applicable, the Quad Chart (available on <https://www.usamraa.army.mil>) should be updated and submitted with attachments.*

Evaluation of hypotensive resuscitation ± aeromedical evacuation and the effects of oxygen therapeutics during prolonged field care in a swine polytrauma model

Prolonged Field Care Research Award

Log Number: DM167102



PI: LCDR Carolyn Gosztyla

Org: Naval Medical Research Center

Award Amount: \$2,834,000

Study Aims

This proposal aims to:

- evaluate the effects of prolonged hypotensive resuscitation up to 72 hours during prolonged field care (PFC).
- evaluate the effects of aeromedical evacuation (AE) after PFC.
- evaluate the effects of oxygen therapeutics (OTs) on oxygen delivery to vital tissues.

Approach

We propose to investigate the clinical implications of PFC and hypotensive resuscitation and test next-generation resuscitation methods. Swine will undergo initial traumatic brain injury and hemorrhagic shock. They will then be kept under prolonged hypotensive resuscitation (PHT) for 72 h. In one study arm, animals will then also undergo aeromedical transportation in a hypobaric chamber to evaluate the effects of transport after PFC. In a third arm, we will test the efficacy of an oxygen therapeutic on oxygen delivery to vital tissues during 72 h of PFC.



Rapid evacuation of combat casualties to CONUS is current standard. However, future conflicts might require prolonged field care for up to 72 h before casualties can be transported to a higher level of care.

Timeline and Cost

Activities	Y1	Y2	Y3	Y4
IACUC/ACURO approval	■			■
Swine polytrauma PFR experiments	■	■		■
Swine polytrauma PFR + AE experiments	■	■		■
Swine polytrauma PFR + OT experiments	■	■	■	■
Data analysis/manuscript/final report				■

Updated: 27AUG21

Goals/Milestones

Y1 Goals

- X IACUC/ACURO protocol written, submitted and approved
- X Initiate swine polytrauma experiments

Y2 Goals

- X Continue swine polytrauma experiments

Y3 Goals

Y4 Goals

- New IACUC/ACURO protocol submission
- Complete swine experiments
- Data analysis
- Manuscript preparation
- Final study report

Comments/Challenges/Issues/Concerns

- Addition of 1 year NCE

Budget Expenditure to Date

Projected Expenditure: \$2,834,000

Actual Expenditure: \$2,710,000

9. **APPENDICES:** *Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.*

N/A